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Introduction: We sought to determine the efficacy of using both iri-
notecan- and etoposide-containing regimens sequentially for patients 
with untreated limited-stage small-cell lung cancer.
Methods: Patients with untreated, measurable, limited-stage small-
cell lung cancer with performance status 0 to 2, and adequate organ 
function were eligible. Treatment consisted of induction with cispla-
tin 30 mg/m2 and irinotecan 65 mg/m2 intravenously on day 1 and 8, 
every 21 days for two cycles. Beginning day 43, daily chest irradia-
tion to 70 Gy was administered concurrently with carboplatin area 
under curve 5 on day 1, and etoposide 100 mg/m2 on days 1 to 3, 
every 21 days for three cycles. The primary objective was to differ-
entiate between 45% and 60% 2-year survival.
Results: Two induction cycles were delivered to 72 of 75 eligible 
patients (96%) and all planned treatment was delivered to 59 patients 
(79%). Cisplatin and irinotecan induction chemotherapy resulted in 
complete responses in 7% and partial responses in 64% (response 
rate 71%, 95% confidence interval [CI], 59%–81%). The best 
response to all therapy included 88% complete or partial responses 
(95% CI, 78%–94%). With median follow-up of 57 months, the 
median progression-free survival and overall survival are 12.6 (95% 
CI, 9.4–14.7) and 18.1 months (15.8–22.9), respectively. The 1- and 
2-year survival was 69% and 31%, respectively. Frequent (>20%) 
grade 3 and 4 toxicities were neutropenia in 84%, hemoglobin in 
36%, platelets in 51%, esophagitis in 22%, and dehydration in 24%. 
There were no fatal toxicities.
Conclusions:  This treatment regimen of irinotecan–cisplatin 
induction chemotherapy followed by 70 Gy concurrent radiation and 
etoposide–carboplatin had tolerable toxicity but did not meet the pre-
planned 2-year survival target for further development.
Key Words: Small-cell lung cancer, Chemotherapy, Radiotherapy, 
Topoisomerase inhibitor.
(J Thorac Oncol. 2013;8: 102–108)
Approximately 13% of lung cancer is the small-cell histo-logical type, which is characterized by initial sensitivity 
to chemotherapy and radiotherapy.1 Chemotherapy improves 
overall survival by more than fourfold, and the addition of tho-
racic radiotherapy further improves both local tumor control 
and survival for patients with limited-stage small-cell lung 
cancer (SCLC), resulting in 2-year survival of approximately 
45% in clinical trials.2 However, most patients with limited-
stage SCLC eventually die of recurrent disease.
The camptothecin, irinotecan, is a prodrug metabolized 
by carboxylesterase to an active metabolite, SN-38, which 
inhibits topoisomerase I.3 Irinotecan has single-agent activ-
ity in previously treated SCLC.4 A Japanese phase III study 
of cisplatin and irinotecan in patients with extensive stage 
SCLC resulted in an improvement of 3 months in median 
survival compared with standard cisplatin and etoposide.5 We 
conducted a phase II study incorporating irinotecan and the 
topoisomerase II inhibitor, etoposide, into the initial treatment 
regimen of patients with untreated limited-stage SCLC to 
determine whether the addition of irinotecan resulted in pre-
liminary evidence of improved outcome.
PATIENTS AND METHODS
Patients
Patients with histologically or cytologically documented 
SCLC of limited-stage and measurable disease were eligible 
for the study. Limited stage was defined as disease restricted 
to one hemithorax with regional lymph node metastases, 
including hilar, ipsilateral, and contralateral mediastinal 
lymph nodes. Patients with clinically suspected or confirmed 
supraclavicular lymph node metastases, patients with 
pathologically enlarged contralateral hilar lymph nodes, 
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and patients with pleural effusions visible on plain chest 
radiographs, whether cytologically positive or not, were not 
eligible. Other requirements included age of at least 18 years, 
Eastern Cooperative Oncology Group performance status 0 to 
2, no active second malignancy, nonpregnant and nonbreast 
feeding, neutrophil count at least 1500/µl, platelet count at 
least 100,000/µl, serum creatinine less than the upper limit 
of normal, bilirubin no greater than 1.5 mg/dl, and serum 
aspartase aminotransferase less than twice the upper limit of 
normal.
Within 28 days before study registration, patients had 
a physical examination, radiographic imaging for baseline 
tumor measurement, complete blood count, and serum chem-
istries (creatinine, blood-urea nitrogen, aspartate transami-
nase, alkaline phosphatase, and total bilirubin). Patients also 
had a chest radiograph, bone scan, computed tomography 
(CT) or magnetic resonance imaging scan of the chest and 
upper abdomen, and CT or magnetic resonance imaging of 
the brain within 42 days before registration. Each participant 
signed an Institutional Review Board–approved, protocol-spe-
cific informed consent in accordance with federal and institu-
tional guidelines.
Treatment
The schema of study-required treatment is shown in 
Figure 1. Induction chemotherapy consisted of cisplatin 30 mg/
m2 per day on days 1 and 8 and irinotecan 65 mg/m2 per day 
on days 1 and 8, for two cycles of 21 days each. Consolidation 
chemotherapy followed immediately after induction and con-
sisted of three 21-day cycles of carboplatin area under the 
curve 5 (using the Calvert formula) on day 1, and etoposide 
100 mg/m2 on days 1 to 3. A cycle of chemotherapy (day 1) 
was delayed up to 3 weeks if the neutrophils were less than 
1500/ul or platelets were less than 100,000 ul; patients with 
longer duration of neutropenia or thrombocytopenia were to 
be removed from study treatment. Prophylactic granulocyte 
growth factor use was discouraged but permitted when used 
per American Society of Clinical Oncology (ASCO) guide-
lines.6 Erythrocyte-stimulating agents were allowed but dis-
couraged during chest radiotherapy.
Chest radiotherapy began concurrently with consolida-
tion chemotherapy and was administered to all patients without 
evidence of progression of disease outside the planned radia-
tion port. Radiotherapy with standard or conformal technique 
was allowed but intensity-modulated radiation therapy was 
prohibited. The total dose was 70 Gy delivered in 2-Gy frac-
tions; an initial 44 Gy was given to the original tumor volume 
(determined on a chest CT scan after induction chemotherapy) 
and potential occult disease sites (ipsilateral hilar, subcarinal, 
and bilateral mediastinal lymph nodes) followed by a 26-Gy 
boost to only the original tumor volume. A single radiation 
field with margins of 1 to 2 cm around target volumes was 
used. Patients achieving a complete response or a very good 
partial response as determined by the treating physician after 
completion of chemotherapy and chest radiotherapy were rec-
ommended to receive prophylactic cranial irradiation starting 
3 to 5 weeks after completion of chemotherapy.
Dose Modifications
Modification of induction chemotherapy doses for neu-
tropenia or thrombocytopenia on day 8 were: for grade 2, 
reduction of irinotecan by 10 mg/m2 and cisplatin by 5 mg/m2; 
for grade 3 and 4, omission of day 8 chemotherapy. Febrile 
neutropenia led to a 25% reduction of both drugs in subsequent 
cycles, however, all patients received full doses of drugs in the 
first cycle of consolidation, unless febrile neutropenia occurred 
in both cycles of induction chemotherapy. Grade 4 thrombocy-
topenia resulted in a 25% reduction of subsequent drugs.
Irinotecan was omitted on day 8 if diarrhea was pres-
ent. The second cycle of cisplatin–irinotecan was delayed if 
diarrhea was present on day 1, cycle 2; diarrhea continuing 
beyond 2 weeks resulted in continuation of cisplatin without 
irinotecan. Grade 2 or 3 diarrhea in cycle 1 resulted in reduc-
tion of irinotecan to 55 mg/m2 and led to grade 4 treatment 
with cisplatin alone.
A cycle of chemotherapy was delayed if creatinine 
was more than 2.0 mg/dl whereas day 8 chemotherapy was 
reduced (cisplatin 67% for creatinine upper limit of normal 
to 2.0; cisplatin omitted and etoposide 50% for creatinine 
2.1–3.0; and delayed for creatinine > 3). Cisplatin or car-
boplatin was reduced by 25% for grade 2 neurotoxicity that 
recovered to grade 1 or better, and omitted for more severe 
toxicity. Treatment breaks in radiotherapy were discouraged 
and required discussion with the radiation cochair.
Outcome Assessment and Statistical Methods
Tumor response was assessed using Response Evaluation 
Criteria in Solid Tumors version 1.0.7 Toxicity was assessed 
using National Cancer Institute Common Toxicity Criteria 
version 3.0. Survival time was measured from the day of 
FIGURE 1.  Schema of study.
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registration until date of death; living patients were censored 
on the date of the last follow-up examination. Progression-
free survival was measured from the day of registration until 
disease progression or death. The method of Kaplan–Meier 
was used to describe survival and progression-free survival. 
The primary end point of the study was based on the proportion 
of patients who were alive 2 years after initiation of protocol 
therapy. The study was designed to differentiate between a 
45% and 60% 2-year survival rate. A one-stage phase II design 
was used. A sample size of 75 would provide 90% power to 
differentiate 2-year survival rates of 45% or less and 60% or 
greater, with a one-sided type I error of 0.091. Secondary 
objectives were to assess the response rates to induction and 
overall therapy, overall and progression-free survival, and 
toxicity. Patient registration and data collection were managed 
by the Cancer and Leukemia Group B (CALGB) Statistical 
Center. Data quality was ensured by careful review of data by 
CALGB Statistical Center staff and by the study chairperson. 
Statistical analyses were performed by CALGB statisticians.
RESULTS
Patients
Seventy-eight patients were enrolled between November 
15, 2003 and September 30, 2005. Three patients were ineli-
gible because of the presence of metastatic disease at the 
time of enrollment; these patients were excluded from the 
efficacy analyses but included in the toxicity assessment. 
Characteristics of the 75 eligible patients are shown in Table 1. 
Fifty-nine patients (79%) completed all protocol therapy. 
Reasons for not completing treatment included progression of 
disease (n = 5), toxicity (n = 4), patient refusal (n = 4), death 
(n = 2), and removal from treatment by treating radiation 
oncologist because of the concern of potential toxicity of the 
radiation protocol treatment (n = 1).
Response
Tumor response evaluation is summarized in Table 2. 
The best patient response to the two cycles of induction cis-
platin–irinotecan chemotherapy was complete response, par-
tial response, and stable disease in 5 (7%), 48 (64%), and 13 
(17%), respectively. One patient had progression, seven were 
unevaluable, and there was one death during the first 6 weeks 
on study because of aspiration. Thus, the overall response rate 
to induction was 71% (95% confidence interval [CI], 59%–
81%). The overall response rate at the completion of all pro-
tocol therapy was 88% (95% CI, 78%–94%) with compete 
response, partial response, and stable disease in 28 (37%), 
38 (51%), and 6 (8%) patients, respectively. One patient each 
had progressive disease, an unevaluable response, and death 
because of other causes.
Survival
After a median follow-up time of 57 months, 64 patients 
had progressed and 61 had died. The median progression-free 
survival was 12.6 months (95% CI, 9.4–14.7 months) and the 
median overall survival was 18.1 months (95% CI, 15.8–22.9 
months) (Table 3 and Figs. 2 and 3). At year 2 only 23 patients 
(31%) were alive.
Recurrence
Four patients had relapsed during radiation therapy, one 
patient (25%) relapsed at both local and distant sites at the 
same time and three patients (75%) had distant relapse only. Of 
the 40 patients who had a relapse during the follow-up period, 
12 patients (30%) relapsed at both local and distant sites at the 
same time, one patient (3%) had distant relapse first and then 
later relapsed locally, eight patients (20%) has local relapse 
only, and 19 patients (48%) had distant relapse only. Overall, 
23 of 37 patients (62%) had relapse outside both the radiation 
field and outside the prechemotherapy tumor volume.
Toxicity
All 78 patients enrolled were available for some toxicity 
evaluation, including 76 patients evaluable for toxicity during 
the two cycles of induction chemotherapy, and 72 patients dur-
ing the consolidation therapy with combined chemotherapy 
TABLE 1.  Characteristics of Eligible Patients (n = 75)
Sex %
 Male 42 56
 Female 33 44
Age, yr
 Median = 61
 Range (min, max) = (41, 79)
 40–49 11 15
 50–59 19 25
 60–69 29 39
 70–79 16 21
Race
 White 73 97
 Black 2 3
Performance status
 0 49 65
 1 26 35
Weight loss
 0% to <5% 64 85
 5% to <10% 4 5
 ≥ 10% 6 8
 Missing data 1 1
TABLE 2.  Best Tumor Response to Treatment (n = 75)
Response Induction (%) Overall (%)
Complete response 5 (7) 28 (37)
Partial response 48 (64) 38 (51)
Stable disease 13 (17) 6 (8)
Progression 1 (1) 1 (1)
Unevaluable 7 (9) 1 (1)
Early death (aspiration day 19) 1 (1) 1 (1)
Overall response rate (95 CI) 71 (59–81) 88 (78–94)
CI, confidence interval.
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and radiotherapy (Table 4). Only three patients (4%) had diar-
rhea of at least grade 3 during induction therapy. Similarly, 
there were infrequent hematologic adverse events during 
induction therapy with only 15 patients (19%) experienc-
ing any grade 3 or 4 hematologic adverse event. Overall, 20 
patients (26%) had grade 3 or 4 adverse event during induc-
tion therapy.
In contrast, during consolidation, 64 patients (89%) 
had grade 3 or 4 hematological toxicity. However, only three 
(4%) required transfusion and only 10 (14%) had febrile neu-
tropenia. Esophagitis occurred in 16 patients (21%) and was 
grade 3 in all but two patients. Other nonhematologic adverse 
events occurring during consolidation were fatigue in nine 
(13%), dehydration in 17 (24%), hypokalemia in seven (10%), 
TABLE 3.  Progression-Free and Overall Survival (n = 75)
Failures/ Deaths (n) 1-Yr Survival (95% CI) 2-Yr Survival (95% CI) Median (95% CI) (mo)
Overall survival 61 69% (61%–81%) 31% (22%–43%) 18.1 (15.8–22.9)
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dysphagia in 13 (18%), and pain in 10 (14%); all were grade 
3 except one patient who had grade 4 pain. Overall, nonhe-
matologic grade 3 or 4 adverse events during consolidation 
therapy occurred in 31 patients (43%) and 8 patients (11%), 
respectively.
Overall, during the entire therapy, hematological and 
nonhematological adverse events of grade 3 or 4 occurred 
in 14 and 57 patients (18% and 73%), respectively. As with 
adverse events observed during induction and consolidation 
therapy, the hematological toxicity was mostly asymptomatic 
and without febrile neutropenia or need for transfusion. 
Diarrhea occurred in 7 patients (9%) during therapy. For the 
most commonly observed grade 3 or 4 toxicity, the rate of 
completing treatment was not different between those with and 
those without dehydration (Fisher’s exact test p = 0.75). None 
of the patients died as a result of an adverse event from therapy.
DISCUSSION
Treatment of patients with extensive stage SCLC with 
cisplatin and irinotecan in the phase III trial by the Japanese 
Clinical Oncology Group (JCOG 9511) resulted in a longer 
median overall survival by 3.4 months compared with survival 
of those treated with cisplatin and etoposide,5 which has been 
a standard first-line treatment for patients with SCLC for 
several decades. However, two larger studies conducted in 
North America have found divergent results. Hanna et al.8 
used an alternate dosing regimen of cisplatin and irinotecan 
with 3-week cycle length and Southwest Oncology Group 
S0124 used an identical chemotherapy dose and schedule as 
the Japanese Clinical Oncology Group (JCOG9511).9 Neither 
of the North American studies showed any statistically 
significant difference in overall survival between the etoposide 
arm and the irinotecan arm.8,9 Recently, a meta-analysis 
of these three studies, plus a fourth phase III study using 
combinations of irinotecan and etoposide with carboplatin in 
extensive stage SCLC,10 showed an improved overall survival 
of irinotecan–platinum over etoposide–platinum with a 
hazard ratio (HR) of 0.81 (95% CI, 0.66–0.99; p = 0.044).11 
However, the study of carboplatin-based combinations used 
oral etoposide, which has previously been shown to result 
in inferior survival12 or greater toxicity13 compared with 
intravenous etoposide in SCLC. When only the three phase III 
studies comparing cisplatin–irinotecan to cisplatin–etoposide 
were included in the meta-analysis, the HR continued to 
favor cisplatin–irinotecan but was not statistically significant 
(HR = 0.85; 95% CI, 0.67–1.07).11 Two European studies, of 
either cisplatin14 or carboplatin15 combinations with irinotecan 
versus a combination with etoposide, both non-significantly 
favored the irinotecan arm with HRs of 0.81 (95% CI, 0.65–
1.01; p = 0.06) and 0.75 (95% CI, 0.54–1.03; p = 0.07), 
respectively. Thus, if there is improvement in survival with 
the use of irinotecan combination chemotherapy in first-line 
treatment of extensive stage SCLC, it is small. Differences 
in efficacy and toxicity of irinotecan-containing regimens 
in these three studies might also have resulted from genetic 
differences in the populations studied, such as the UGT1A1 
polymorphism associated with increased toxicity from high 
doses of irinotecan.16
In limited-stage SCLC, the addition of chest radiother-
apy to chemotherapy results in improved overall survival, 
TABLE 4.  Adverse Eventsof Grade 3 or 4 Severity and At Least 10% Incidence During Induction (n = 76), Consolidation  
(n = 72), and Overall Therapy (n = 78)
Type of Toxicity
Induction Grade, n (%) 
Consolidation Grade, Consolidation Grade, n (%) Overall Grade, n (%)
3 4 3 4 3 4
Hematologic AEs
Hemoglobin 1 (1) 0 (0) 27 (38) 0 (0) 28 (36) 0 (0)
Leukocytes 4 (5) 1 (1) 30 (42) 29 (40) 32 (41) 29 (37)
Lymphopenia 2 (3) 0 (0) 5 (7) 5 (7) 7 (9) 5 (6)
Neutrophils 11 (14) 3 (4) 14 (19) 46 (64) 19 (24) 47 (60)
Platelets 1 (1) 1 (1) 19 (26) 20 (28) 19 (24) 21 (27)
Maximum hematologic AE 11 (14) 4 (5) 10 (14) 54 (75) 12 (15) 56 (72)
Nonhematologic AEs
Fatigue 1 (1) 0 (0) 9 (13) 0 (0) 11 (14) 0 (0)
Dehydration 1 (1) 1 (1) 17 (24) 0 (0) 18 (23) 1 (1)
Diarrhea 2 (3) 1 (1) 3 (4) 0 (0) 6 (8) 1 (1)
Dysphagia 0 (0) 0 (0) 13 (18) 0 (0) 13 (17) 0 (0)
Esophagitis 1 (1) 0 (0) 14 (19) 2 (3) 15 (19) 2 (3)
Febrile neutropenia 1 (1) 0 (0) 8 (11) 2 (3) 9 (12) 2 (3)
Hypokalemia 1 (1) 0 (0) 0 (0) 8 (10) 0 (0)
Pain 1 (1) 0 (0) 9 (13) 1 (1) 11 (14) 1 (1)
Maximum nonhematologic AE 9 (12) 1 (1) 31 (43) 8 (11) 37 (47) 9 (12)
Maximum overall AE 16 (21) 4 (5) 12 (17) 55 (76) 14 (18) 57 (73)
AE, adverse event.
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with the best outcome observed when radiotherapy is given 
concurrently with chemotherapy.17,18 However, concurrent 
administration of irinotecan during radiotherapy results in 
toxicity, limiting the dose of irinotecan to less than full dose 
tolerated without radiotherapy. In SCLC, some studies have 
attempted to administer chest radiotherapy and irinotecan-
containing chemotherapy concurrently to patients with lim-
ited-stage SCLC. Two dose-escalation studies of irinotecan 
given concurrently with cisplatin and chest radiotherapy 
demonstrated tolerability when used with either split-
course chest radiotherapy,19 or standard daily fractionation,20 
although the recommended irinotecan dose varied between 
the studies. In contrast, a Dutch dose-escalation study 
administering cisplatin and irinotecan in a single dose once 
every 3 weeks resulted in excessive radiation-associated tox-
icity.21 In a multisite phase II study of two cycles of induc-
tion cisplatin–irinotecan followed by weekly irinotecan with 
concurrent chest radiotherapy, only 56% of patients were 
able to receive the full planned treatment.22 Two small, sin-
gle-institution phase II studies of cisplatin–irinotecan che-
motherapy, in which the irinotecan dose was approximately 
66% of full dose without radiotherapy, combined with chest 
radiotherapy confirmed tolerability but each had a nearly 
identical median survival of 20 months.23,24 A third single-
institution study of 37 patients using a similar design had a 
median survival of 26 months.25
An alternative approach to concurrent irinotecan and 
radiation is sequential therapy with an alternative chemo-
therapy being administered during radiation. Two early-phase 
Japanese studies that used nearly identical treatment schemata 
consisting of cisplatin and etoposide for one cycle with twice 
daily chest radiotherapy followed by three cycles of cisplatin 
and irinotecan chemotherapy have been completed.26,27 The 
response rates were 88% to 97% and median survival times 
were 20 and 23 months, respectively. These results were the 
basis of a phase III study by the Japanese Clinical Oncology 
Group (JCOG 0202), which has preliminarily been reported 
to show no difference between the irinotecan and etoposide 
arms (HR = 1.085, 95% CI, 0.80–1.46; p = 0.70).28 A single-
institution Korean phase II study using the opposite order of 
regimens (2 cycles of cisplatin and irinotecan followed by 2 
cycles of cisplatin and etoposide with 45 Gy twice daily chest 
radiotherapy) also demonstrated efficacy with a response of 
97% and medial survival of 25 months.29
Our study also used a sequential approach and built 
upon two previous CALGB studies that examined paclitaxel 
and topotecan with filgrastim, (CALGB 39808)30 or pacli-
taxel–topotecan–etoposide with filgrastim (CALGB 30002)31 
for the first two cycles of chemotherapy, followed by three 
cycles of carboplatin–etoposide with 70 Gy chest radiation 
in single daily fractions. The use of a similar design in the 
current study allowed us to indirectly compare results of this 
study with the those of previous, similarly designed studies, as 
well as evaluate the activity of cisplatin irinotecan in untreated 
limited-stage SCLC. The overall survival was shorter in the 
current study (18 months) compared with CALGB 39808 
(22 months) and CALGB 30002 (20 months), despite using 
identical chemoradiotherapy after the first two cycles of che-
motherapy and having similarity in the characteristics of the 
enrolled patients. A subset of 26 patients in CALGB 30002 
had data on location of relapse, of whom 58% had relapse out-
side both the radiation field and the prechemotherapy tumor 
volume, similar to the rate of distant relapse observed in this 
trial (62%). In addition to using daily radiotherapy fraction-
ation, these three CALGB studies began chest radiotherapy 
concurrent with the third cycle of chemotherapy, which has 
been suggested to contribute to accelerated repopulation and 
poorer outcome relative to earlier initiation of chest radiother-
apy.32 However, a recently reported phase III study comparing 
initiation of concurrent chemoradiotherapy on the first or third 
cycle showed no difference in overall survival.33
The response rate after two cycles of cisplatin-irinote-
can in our study (71%) was similar to the 64% response rate 
reported among 61 patients in a phase II study of carboplatin–
irinotecan in patients with anatomically limited disease, who 
were not fit to receive chest radiotherapy.34 Not unexpectedly, 
the overall survival was longer in our study (18.1 months ver-
sus 13.8 months).34 However, the 2-year survival rate of 31% 
fell well short of the predetermined target of 60% to justify 
further investigation of the treatment studied here. Although 
the predetermined target might be overly ambitious and the 
toxicity of the treatment regimen was manageable, there is 
insufficient efficacy to support either the use of this treatment 
in clinical practice or further investigation.
New strategies for augmenting median and overall 
survival among patients with limited-stage SCLC are needed. 
To that end, the current phase III intergroup study for limited-
stage SCLC (CALGB 30610) compares the once-daily chest 
radiotherapy of 70 Gy, as used in this study, with two other 
chest radiation dosing plans. Several recent therapeutic 
advances in cancers other than SCLC have exploited specific 
somatically acquired genetic defects targeted by small-
molecule inhibitors, such as erlotinib and crizotinib in non–
SCLC and vemurafenib in melanoma. In contrast, SCLC 
contains a large number of genetic alterations,35 therefore, 
identifying and therapeutically modulating the key targets has 
proven difficult. In addition to targeted agents, new treatment 
approaches such as novel cytotoxic agents and refinements in 
radiotherapy show promise for improvement in outcome for 
patients with SCLC.36
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